Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab Combined With AVD in Newly-diagnosed Advanced Classic Hodgkin Lymphoma
NCT05949931Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of penpulimab in classic Hodgkin lymphoma (cHL) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Complete response rate at 48 weeks. Started Oct 2023; status: recruiting.
02
Drugs
penpulimab
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05949931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949931.